Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by Adagene (Suzhou) Limited

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masked antibody drug conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Recipient: Tanabe Research Laboratories

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 10, 2020

            Details:

            Under the terms of this collaboration, TRL will use Adagene’s SAFEbody™ technology platform to generate a masked antibody in combination with the cytotoxic payload technologies used at TRL, for the development of an ADC against a solid tumor target.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adg106

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: General Atlantic

            Deal Size: $69.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing January 08, 2020

            Details:

            Proceeds will support advancement of lead immunotherapy clinical programs ADG106 and extend the frontiers of novel technology.